Plasma sRAGE is independently associated with high sensitivity C-reactive protein in type 2 diabetes without coronary artery disease

Diabetes Research and Clinical Practice

Volumn 87, Issue 3, 2010, Pages

  An, Xiao Fei ^a   Zhao, Yue ^a   Yu, Jiang Yi ^a   Liu, Jing Shun ^a   Gu, Wan Jian ^a   Gao, Feng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Carboxymethyllysine (CML); High sensitivity C reactive protein (hs CRP); Soluble receptor for advanced glycation end products (sRAGEs); Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLASMA SOLUBLE ADVANCED GLYCATION END PRODUCT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY MASS; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SYSTOLIC BLOOD PRESSURE;

AGED; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS;

EID: 77649189667     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.12.005     Document Type: Article

References (19)

1. Sugimoto K., Yasujima M., and Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr. Pharm. Des. 14 (2008) 953-961
2. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin M.J., Li H., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370 (2003) 1097-1109
3. Falcone C., Emanuele E., D'Angelo A., Buzzi M.P., Belvito C., Cuccia M., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1032-1037
4. Nakamura K., Yamagishi S., Adachi H., Kurita-Nakamura Y., Matsui T., Yoshida T., et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab. Res. Rev. 23 (2007) 368-371
5. Lloyd-Jones D.M., Liu K., Tian L., and Greenland P. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann. Intern. Med. 145 (2006) 35-42
6. Pai J.K., Pischon T., Ma J., Manson J.E., Hankinson S.E., Joshipura K., et al. Inflammatory markers and the risk of cornary heart disease in men and women. N. Engl. J. Med. 351 (2004) 2599-2610
7. Bruno G., Fornengo P., Novelli G., Panero F., Perotto M., Segre O., et al. C-reactive protein and 5-year survival in type 2 diabetes: the Casale Monferrato Study. Diabetes 58 (2009) 926-933
8. Schulze M.B., Rimm E.B., Li T., Rifai N., Stamper M.J., and Hu F.B. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 27 (2004) 889-894
9. Yeh E.T. High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. Clin. Cardiol. 28 (2005) 408-412
10. Gao X., Zhang H., Schmidt A.M., and Zhang C. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am. J. Physiol. Heart Circ. Physiol. 295 (2008) H491-498
11. Geroldi D., Falcone C., and Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem. 13 (2006) 1971-1978
12. Wendt T., Harja E., Bucciarelli L., Qu W., Lu Y., Rong L.L., et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 185 (2006) 70-77
13. Park L., Raman K.G., Lee K.J., Lu Y., Ferran Jr. L.J., Chow W.S., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4 (1998) 1025-1031
14. Katakami N., Matsuhisa M., Kaneto H., Matsuoka T.A., Sakamoto K., Yasuda T., et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 204 (2009) 288-292
15. Nakamura K., Yamagishi S., Adachi H., Kurita-Nakamura Y., Matsui T., Yoshida T., et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol. Med. 13 (2007) 185-189
16. Nakou E.S., Liberopoulos E.N., Milionis H.J., and Elisaf M.S. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr. Vasc. Pharmacol. 6 (2008) 258-270
17. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 32 (2009) S13-S61
18. Basta G., Sironi A.M., Lazzerini G., Turco S.D., BuzzigolE. I., Casolaro A., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J. Clin. Endocrinol. Metab. 91 (2006) 4628-4634
19. Nakamura K., Yamagishi S., Adachi H., Matsui T., Kurita-Nakamura Y., Takeuchi M., et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc. Res. 76 (2008) 52-56